Anna N. A. Tosteson, ScD
Title(s)
Interim Director and Professor of The Dartmouth Institute
Professor of Medicine
Professor of Community and Family Medicine
James J. Carroll 1948 Professor of Oncology
Additional Titles/Positions/Affiliations
Director, Comparative Effectiveness Research Program, The Dartmouth Institute for Health Policy and Clinical Practice
Associate Director for Population Sciences, Norris Cotton Cancer Center
Associate Director, SYNERGY, Dartmouth's Clinical and Translational Science Institute
Department(s)
The Dartmouth Institute
Medicine
Community and Family Medicine
Education
Biostatistics (Health Decision Sciences), Harvard University, ScD
Biostatistics, Harvard University, MS
Statistics & Biometry, Cornell University, BS
Programs
Norris Cotton Cancer Center
SYNERGY
The Dartmouth Institute for Health Policy and Clinical Practice
Contact Information
Dartmouth Medical School
HB 7505
One Medical Center Drive
Lebanon NH 03756
Office: WTRB 526, DHMC
Phone: 603-653-3568
Email: Anna.Tosteson@dartmouth.edu
Assistant: Christopher Jacobs
Asst. Phone: 603-653-0802
Asst. Email: Christopher.R.Jacobs@Dartmouth.EDU
Professional Interests
Dr. Anna Tosteson is a decision scientist and health services researcher who studies how the diffusion of innovations in health care are changing health, costs and quality of care. Through study of diverse data sources including registries, clinical and epidemiological studies, and administrative claims data, she seeks insights into the long-term clinical and economic effects of alternative approaches to health care delivery with a focus on cancer screening, musculoskeletal disease, and women’s health.
Grant Information
Promoting follow-up of abnormal cancer screening tests using population-based systems to support stepped care multilevel intervention. (NCI: U01CA225451 )
Risk-based breast cancer screening and surveillance in community practice. (NCI, P01CA154292)
Courses Taught
PH 119/121; QBS 140 Decision and Cost-Effectiveness Analysis
Selected Publications |
|
Sacubitril/Valsartan vs. ACEi/ARB at Hospital Discharge and 5-Year Survival in Older Patients with Heart Failure with Reduced Ejection Fraction: A Decision Analysis Approach. Factors Influencing Telemedicine Use at a Northern New England Cancer Center During the COVID-19 Pandemic. Breast Density Knowledge in a Screening Mammography Population Exposed to Density Notification. Cumulative Probability of False-Positive Results After 10 Years of Screening With Digital Breast Tomosynthesis vs Digital Mammography. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis. A Procedure for Eliciting Women's Preferences for Breast Cancer Screening Frequency. Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population. Comparing Mammographic Density Assessed by Digital Breast Tomosynthesis or Digital Mammography: The Breast Cancer Surveillance Consortium. Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield. Breast Biopsy Recommendations and Breast Cancers Diagnosed during the COVID-19 Pandemic. |
|